TabletsClinical Overview
Cinnarizine (20mg) and Domperidone (15mg) Tablets is a dual-action vestibular sedative and antiemetic combination. Cinnarizine acts as a selective T-type voltage-gated calcium channel blocker and H1-antihistamine, suppressing labyrinthine overstimulation in the inner ear. Domperidone blocks peripheral dopamine D2 receptors in the CTZ, preventing motion-induced and labyrinthine nausea. Indicated for vertigo, motion sickness, Meniere's disease, and peripheral vestibular disorders accompanied by nausea and vomiting.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, 1 tablet twice or thrice daily, preferably after meals to reduce stomach upset. For motion sickness, take 1 tablet 2 hours before travel.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Somnolence, fatigue, dry mouth, weight gain, dyspepsia. Rare/Severe: Extrapyramidal symptoms (tremors, parkinsonism in elderly from cinnarizine), and cardiac arrhythmia risk (domperidone).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Causes marked drowsiness; avoid driving or operating machinery. Avoid prolonged continuous therapy in elderly patients due to risk of drug-induced Parkinsonism from cinnarizine.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Domperidone Tablets 10 mg
Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.
Domperidone Suspension 5mg per 5ml
Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.
Omeprazole 20mg + Domperidone 10mg Capsules
Omeprazole (20mg gastro-resistant) and Domperidone (10mg/30mg sustained-release) is a cornerstone fixed-dose PPI and prokinetic combination on the WHO Model List framework. Omeprazole irreversibly suppresses gastric acid secretion by inhibiting parietal cell H+/K+-ATPase. Domperidone blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, stimulating gastric motility and preventing acid reflux. Indicated for gastroesophageal reflux disease, non-ulcer dyspepsia, and peptic ulcer disease accompanied by nausea, fullness, or vomiting.
Rabeprazole 20mg (Enteric Coated) + Domperidone 30mg (Sustained Release) Capsules
Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).